A new potential breakthrough drug is being tested by Shigemi Matsuyama at Case Western Reserve University School of Medicine with a grant from the Foundation Fighting Blindness. The grant aims to develop an oral medicine for retinitis pigmentosa (RP) that can prevent blindness regardless of the genetic mutation. RP causes blindness by killing light-responsive cells in the retina. Matsuyama’s research team previously developed cell-death inhibitors that prevented vision loss in mouse models of inherited retinal disease. The new studies include toxicology evaluation and drug formulation testing to advance the therapy to U.S. FDA-regulated clinical trials. The Foundation Fighting Blindness is proud to support Matsuyama’s research in finding solutions for inherited retinal diseases.
Source link
Case Western Reserve University receives $1.5M grant for oral drug trial to prevent blindness in RP patients
